• Sample Page

Author: admin

  • Winter of the Crow review – Lesley Manville commands cold war thriller | Toronto film festival 2025

    Winter of the Crow review – Lesley Manville commands cold war thriller | Toronto film festival 2025

    The specific brilliance of Lesley Manville had been on display for those who knew where to look long before her first Oscar nomination. She’d been part of the enviable Mike Leigh troupe (her first nomination should have been for Another Year) and a permanent small-screen fixture, even if the size of her roles hadn’t correlated to the size of her talent. But after Phantom Thread, Paul Thomas Anderson’s singular magnum opus, Manville has enjoyed a spectacular boom, a long-deserved reward for her and an even bigger one for those of us watching.

    The role came as she was entering her 60s, a period that can often leave female actors with grimly limited options, but she’s bucked the trend, not just through the sheer amount of work she’s found but also the unusual variety. She’s avoided the post-Book Club subgenre of mostly patronising comedies that squander older actors on pained pratfalls and found herself in far more interesting, and challenging, territory. She was a wife experiencing later stage sexual dissatisfaction in I Am Maria, a vicious Ma Barker type reigning over a North Dakota family of criminals in Let Him Go, a gun-toting ayahuasca-farming jungle doctor in Queer, the devious antagonist of the spy series Citadel, a cleaner turned fashionista in Mrs Harris Goes to Paris and an OnlyFans stripper in Ryan Murphy’s Grotesquerie. It’s hard to think of many post-Oscar recognition careers that have been quite so uniquely rewarding.

    She was last at the Toronto film festival with a cruelly small role in Patrick Marber’s cruelly underwhelming trifle The Critic but returns with a welcome lead, switching it up again with the tense cold war thriller Winter of the Crow. She plays Joan, a British professor of psychiatry heading to Poland to speak at a conference, hoping to share her provocative thoughts on treating mental illness. But while she was steeling herself for backlash from academia, she wasn’t expecting a student uprising, her big moment stolen by those wishing to speak out against the government. Her annoyance at both the protesters and her treatment (lost bag, no hotel, a night on the couch) soon dissipates when she starts to realise something bigger is going down around her. She’s landed near the end of 1981 as the country prepares to enter martial law …

    The unfolding awfulness of her situation, as a language disconnect and increasingly barbaric forces shrink her from slightly haughty academic to panicked woman on the run, makes for a nervy and immediately involving thriller. Director Kasia Adamik (daughter of Agnieszka Holland and storyboard artist for Catwoman and Battlefield Earth!) blurs the line between the stark reality of her predicament and the horror of a recurring nightmare, an inescapable maze of brutalist greyness, danger at every corner. It’s all very dank and murky but there’s a real jolt to the initial cat-and-mouse chase as we watch a woman of proud competence realise she’s unable to rely on her usual armory. Adamik’s decision to provide subtitles to characters she can’t understand is initially alienating, taking us out of our heroine’s head, but it’s a decision that grew on me, a smart way of increasing tension and reminding Joan of the narrowness of her world.

    Her journey is first physically exhausting and then morally challenging as she must figure out what she believes in and how far she’s willing to go for the greater good, an inner conflict that lands her at the feet of Tom Burke’s shady British ambassador. An earlier scene of her in England, letting down a frustrated student, is a little rushed and confusing but eventually feeds into a through-line of Joan realising she needs to respect and connect to the political desires of those younger than her. It doesn’t quite fall into place as I think the makers intended – the pace sags in the middle, there’s some limply mechanical delivery of backstory and there’s the use of a Polaroid camera to conveniently capture evidence that starts to stretch credulity – but it all builds to a quietly rousing plane set piece, a far more muted version of the Argo finale. Since 1981, the story of an intrepid rebellion fighting back against an authoritarian government hasn’t ever lacked relevancy but it’s obviously an easy story to get behind at this particular moment.

    Adamik, working from a short story by Olga Tokarczuk, isn’t always able to keep us in her grip, but Manville, driven and determined as ever, never lets us go.

    Continue Reading

    September 7, 2025
  • I found this new Obsidian feature so good, I might uninstall all the other productivity apps

    I found this new Obsidian feature so good, I might uninstall all the other productivity apps

    Like many Obsidian users, I have spent countless hours trying to find the perfect system to manage my notes, projects, and ideas. While Obsidian’s core features are powerful, I have always felt there was a major gap when it came to structured data. The need to create databases, manage lists, and visualize information in a clean, organized way often forced me to rely on other applications.

    That all changed with the introduction of Obsidian Bases. This new core feature has reshaped my vault and allowed me to build robust, interactive databases directly on top of my existing notes. Although Bases is in the early stages, it is good enough to replace my databases in other apps.

    What is Obsidian Bases?

    Unlock databases

    I have always loved the flexibility of Obsidian, but my workflow felt incomplete. I would have all my thoughts and notes interconnected, yet as soon as I needed any kind of structure (a project list, a content calendar, or even a simple reading list), the system broke down.

    The community was quick to point me to plugins like Dataview, a powerful tool that could query my notes and display them in a table. It was incredible in theory, but in practice, I found it clunky.

    I spent a couple of hours trying to learn a new syntax just to get a basic list of my projects, and the process felt more like programming than note-taking.

    Then came Obsidian Bases. I can now simply use the command menu and insert a database with a single click. I can drag and drop columns, filter my notes with a few clicks, and even switch between different views like a table or list. Bases finally gave me the power of structured data without the painful learning curve.

    Obsidian Bases features

    Good enough for v1.0

    Obsidian Bases properties

    Since its launch, I have been exploring Obsidian Bases, and I have found it to be solid and exactly what I needed. Obsidian bases are quite different from Notion. When you create a new database on any page, it pulls up all the pages from your vault (even if there are thousands of them).

    From there, I can filter notes based on specific conditions and find my relevant notes in no time. I can even select Properties and start adding relevant columns to the Bases (more on that in a minute).

    The first thing I noticed was the speed. Navigating through thousands of notes in a base is incredibly fast, which is a major advantage over other community plugins and rival tools like Notion.

    I can’t tell you how many times I ran into loading indicators when dealing with large Notion databases.

    I can now create a table view for a quick overview of all my projects and then switch to a card view for a more visual, Kanban-style layout.

    Even though this is just the first version of Obsidian Bases, it feels robust and complete. It shows that a well-designed core feature can be far more effective than a collection of third-party plugins.

    Obsidian Bases in action

    Organize info like a pro

    Bases offers a practical, real-world solution to the organizational problems I have always had. Let me walk you through some of the databases I have created.

    My first and most impactful database is for project management. Before Bases, I had project notes everywhere in my vault. Now, I have a single base that pulls every note tagged with #project or #task. Each row in this table is a project note or a task.

    I can add a column with task status, priority, a simple number, and more. I have added another database where I display all my Obsidian templates.

    I have also built a simple Reading List base that I love. Every book note I create goes into this database. The properties (columns) I use are Author, Rating, Status, and Date Finished. I can quickly filter this database to see all the books I want to read next or sort by rating to see my all-time favorites. It’s a clean, simple, and powerful way to keep track of everything without ever leaving Obsidian.

    If you have given up on Obsidian because of the lack of databases, I highly recommend giving Bases a try. It’s not just limited to power users only. This tool can transform any workflow that needs a little bit of structure. It does require a learning curve, though. It is fundamentally different from other Notion databases.

    Obsidian Bases is a game-changer

    The introduction of Obsidian Bases didn’t just add another feature to my favorite note-taking app; it fundamentally changed how I work. Now, I no longer need to deal with another app or a spreadsheet for tackling a project or creating a database.

    Of course, it’s far from perfect. If you are used to Notion’s database types or automation, you may feel left wanting more. The good news is, Obsidian developers already have a solid plan for Bases, and I can’t wait to see how they take it to the next level with future updates (I would love to see more view types and properties for columns).

    Continue Reading

    September 7, 2025
  • Sun Hung Kai Properties (HKG:16) Has Announced A Dividend Of HK$2.80

    Sun Hung Kai Properties (HKG:16) Has Announced A Dividend Of HK$2.80

    The board of Sun Hung Kai Properties Limited (HKG:16) has announced that it will pay a dividend of HK$2.80 per share on the 20th of November. Including this payment, the dividend yield on the stock will be 4.1%, which is a modest boost for shareholders’ returns.

    This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

    Sun Hung Kai Properties’ Future Dividend Projections Appear Well Covered By Earnings

    Even a low dividend yield can be attractive if it is sustained for years on end. Prior to this announcement, Sun Hung Kai Properties’ dividend was comfortably covered by both cash flow and earnings. This indicates that quite a large proportion of earnings is being invested back into the business.

    Over the next year, EPS is forecast to expand by 35.0%. If the dividend continues on this path, the payout ratio could be 43% by next year, which we think can be pretty sustainable going forward.

    SEHK:16 Historic Dividend September 7th 2025

    Check out our latest analysis for Sun Hung Kai Properties

    Dividend Volatility

    The company’s dividend history has been marked by instability, with at least one cut in the last 10 years. The annual payment during the last 10 years was HK$3.35 in 2015, and the most recent fiscal year payment was HK$3.75. This implies that the company grew its distributions at a yearly rate of about 1.1% over that duration. It’s encouraging to see some dividend growth, but the dividend has been cut at least once, and the size of the cut would eliminate most of the growth anyway, which makes this less attractive as an income investment.

    Sun Hung Kai Properties May Find It Hard To Grow The Dividend

    With a relatively unstable dividend, it’s even more important to evaluate if earnings per share is growing, which could point to a growing dividend in the future. In the last five years, Sun Hung Kai Properties’ earnings per share has shrunk at approximately 3.9% per annum. Declining earnings will inevitably lead to the company paying a lower dividend in line with lower profits. Earnings are predicted to grow over the next year, but we would remain cautious until a track record of earnings growth is established.

    In Summary

    In summary, while it’s good to see that the dividend hasn’t been cut, we are a bit cautious about Sun Hung Kai Properties’ payments, as there could be some issues with sustaining them into the future. In the past, the payments have been unstable, but over the short term the dividend could be reliable, with the company generating enough cash to cover it. This company is not in the top tier of income providing stocks.

    Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For instance, we’ve picked out 1 warning sign for Sun Hung Kai Properties that investors should take into consideration. Is Sun Hung Kai Properties not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks.

    New: Manage All Your Stock Portfolios in One Place

    We’ve created the ultimate portfolio companion for stock investors, and it’s free.

    • Connect an unlimited number of Portfolios and see your total in one currency
    • Be alerted to new Warning Signs or Risks via email or mobile
    • Track the Fair Value of your stocks

    Try a Demo Portfolio for Free

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

    September 7, 2025
  • Elvis Presley documentary ‘EPiC’ lets the King tell his own story

    Elvis Presley documentary ‘EPiC’ lets the King tell his own story

    TORONTO – Baz Luhrmann made his version of Elvis Presley’s legend with “Elvis.” And with his latest movie, the director lets the King of Rock ‘n’ Roll tell his own story.

    Not a documentary, not a concert, but “a tone poem,” Luhrmann says, “EPiC: Elvis Presley in Concert” showcases electrifying rehearsal and concert footage never seen before from Presley’s Las Vegas residency at the International Hotel from 1969 to 1976. The Australian filmmaker was on hand to premiere the film Sept. 6 at Toronto Film Festival, where the audience stood up and danced to hits like “Suspicious Minds” and more from the Presley catalog.

    When getting ready to make his 2022 movie “Elvis” starring Austin Butler, Luhrmann said he had heard about some “mythical footage” that he wanted to research. The filmmaker had the resources to go into “the salt mines in Kansas” where Warner Bros. had stored negatives and found 59 hours of footage – 15 hours of it with no sound at all.

    Join our Watch Party!  Sign up to receive USA TODAY’s movie and TV recommendations right in your inbox

    According to Jonathan Redmond, Luhrmann’s longtime editor, all the music performances and rehearsal tracks were in hand; they just had to sync it up with the found footage. That ended up being a two-year job.

    During that process, one thing really impressed Luhrmann about Presley: “It doesn’t matter what’s going on, it doesn’t matter what condition he is, he is never out of tune,” the filmmaker said. “And he’s always spiritual when he sings.”

    “EPiC” gives a little history of Presley leading up to the Vegas years, from being drafted into the Army to becoming a Hollywood star. He didn’t love the films he was making, which led to the residency. “He said, ‘I need to show the audience what I can do. I need to get back to being Elvis.’ And that is what drove him,” said Luhrmann.

    The striking thing about both the rehearsal and concert footage is it shows how vital Elvis still was a performer, hip thrusts, kung fu moves and all. He does a little tap dancing when Sammy Davis Jr.’s in the crowd. Presley banters with the audience when they’re not trying to hug him (he does kiss many a fan, too). But it’s his sense of humor that comes through most in “EPiC”: Rehearsing The Beatles’ “Something,” Presley croons, “Something in the way she moves …” and he quips to his band, “These are suggestive lyrics, man.”

    Something else that Luhrmann found in their digging: Presley spoke to his band for 45 minutes, unbroken on tape, “about his life and he was so unguarded,” he said. The movie includes pieces of that, including Presley stating, “There’s a lot being said, but I’d like to have the opportunity to tell my side of the story.”

    That prompted Luhrmann to “let Elvis sing and tell his story himself. And that was really the choice. Kind of a dream.”

    Continue Reading

    September 7, 2025
  • CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC

    CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC

    Perioperative Nivolumab QOL Outcomes in Resectable NSCLC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

    Perioperative nivolumab (Opdivo) did not negatively impact health-related quality of life (HRQOL) and reduced the risk of deterioration compared with placebo, irrespective of nodal status or surgical outcomes, in patients with stage III N2 or non-N2 non–small cell lung cancer (NSCLC), according to long-term data from the phase 3 CheckMate 77T trial (NCT04025879) presented during a press briefing at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.1

    The study evaluated HRQOL by nodal status and surgical outcomes by leveraging patient-reported outcome (PRO) measures like the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual analogue scale (VAS). Findings from the exploratory analysis showed that those with stage III N2 disease had a lower risk of HRQOL deterioration and delayed median time to definitive deterioration (TTDD) with nivolumab vs placebo, including those with simple lobectomy or complete resection based on NSCLC-SAQ total scores (HR, 0.45; 95% CI, 0.26-0.79) and EQ-5D-3L VAS (HR, 0.53; 95% CI, 0.31-0.92).

    Specifically, according to the NSCLC-SAQ instrument, the TTDD was 44.5 months in the nivolumab arm (n = 91) vs 31.4 months in the placebo arm (n = 90). The 12-, 24-, and 30-month TTDD rates in the respective arms were 88% and 69%, 77% and 55%, and 77% and 53%. According to the EQ-5D-3L VAS instrument, the median TTDD was 44.5 months with nivolumab and 35.7 months with placebo. In the nivolumab arm, the TTDD rates at 12, 24, and 30 months were 81%, 77%, and 73%; in the placebo arm, these rates were 66%, 53%, and 53%.

    “What’s important to note is that both in the N2 and non-N2 patients, if you look at departure of baseline QOL, other than the brief period after surgery, most patients remain within the nonclinically significant range, indicating that perioperative nivolumab did not harm these patients,” Jonathan D. Spicer, MD, PhD, medical director of the Thoracic Oncology Program at McGill University Health Centre, in Montreal, Quebec, said in the briefing. “In fact, it provided benefit in a significant majority of them, and this is durable throughout the course of observation.”

    CheckMate-77T: What Is the Significance of the Trial, and What Prior Data Have Read Out?

    The randomized, global, phase 3 study showed that perioperative nivolumab led to a statistically significant and clinically meaningful event-free survival (EFS) benefit and an improved pathologic complete response (pCR) rate vs placebo plus chemotherapy in patients with resectable NSCLC.2 The median EFS was not reached (NR; 95% CI, 28.9-not estimable) in the nivolumab arm vs 18.4 months (95% CI, 13.6-28.1) in the placebo arm (HR, 0.58; 95% CI, 0.43-0.78; P = .00025).3

    The data supported the October 2024 FDA approval of nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment followed by nivolumab monotherapy after surgery as adjuvant treatment for adults with resectable NSCLC without EGFR mutations or ALK rearrangements.

    In a past interview with OncLive®, Mark Awad, MD, PhD, of Memorial Sloan Kettering Cancer Center, in New York, NY, discussed the significance of the trial and the approval:4 “What CheckMate 77T and other [trials] are beginning to show is that using chemotherapy and immunotherapy before surgery, and immunotherapy after surgery, significantly reduces the risk of recurrence. As patients are followed more longitudinally in these trials, we’re seeing a clear separation in terms of how often the cancer tends to come back, depending on whether patients were randomly assigned to the arm of the trial that included immunotherapy, or to the placebo arm of the trial, where patients only received chemotherapy before surgery but did not receive immunotherapy before or after surgery. This is an exciting development in early-stage lung cancer.”

    Findings shared during the 2024 ASCO Annual Meeting showed that clinical benefit was observed with perioperative nivolumab vs placebo in those with stage III N2 NSCLC, at a median EFS of 30.2 months (95% CI, 26.9-not reached) vs 10.0 months (95% CI, 8.1-15.1; HR, 0.46; 95% CI, 0.30-0.70).5 The pCR rates in the respective arms were 22.0% and 5.6% (difference, 16.4%). These benefits were also observed in those with single- (HR, 0.49; 95% CI, 0.29-0.84) or multistation (HR, 0.43; 95% CI, 0.21-0.88) N2 NSCLC, and those with stage III non-N2 NSCLC (HR, 0.60; 95% CI, 0.33-1.08).

    What Else Was Learned From the Current QOL Analysis?

    HRQOL was evaluated per mean changes from baseline NSCLC-SAQ or EQ-5D-3L VAS scores was maintained among patients with stage III N2 NSCLC who had simple lobectomy or complete resection.1

    Specifically, per the NSCLC-SAQ instrument, the median TTDD was NR in those who received nivolumab and had a simple lobectomy (n = 58) vs 36.0 months in those who received placebo (n = 49; HR, 0.41; 95% CI, 0.21-0.82). By the EQ-5D-3L VAS instrument, those who received nivolumab and had a simple lobectomy experienced a median TTDD of 50.8 months vs 3.57 months with placebo (HR, 0.35; 95% CI, 0.17-0.69). By the NSCLC-SAQ instrument, the median TTDD was 44.5 months in those who received nivolumab and achieved complete resection (n = 60) vs 36.0 months with placebo (n = 57; HR, 0.48; 95% CI, 0.24-0.93). By the EQ-5D-3L VAS instrument, the median TTDD was 50.8 months with nivolumab vs NR with placebo (HR, 0.37; 95% CI, 0.18-0.76).

    “Looking at the impact of surgical outcomes, specifically the extent of resection and the completeness of resection, we see benefits in terms of TTDD for patients who had a simple lobectomy, as well as those with complete resection; this was true both on the symptom assessment and visual analog scales,” Spicer explained. “The number of patients with R+ resections or extended lobectomies was few, and therefore, we cannot generate curves to represent those patients.”

    He concluded by saying that these findings further support perioperative nivolumab as an efficacious treatment option in eligible patients with resectable NSCLC, including those with stage III N2 disease.

    Editor’s Note: No disclosures were listed.

    References

    1. Spicer JD, Pulla MP, Cascone T, et al. Patient-reported outcomes with perioperative nivolumab by nodal status in patients with resectable NSCLC from CheckMate 77T. Presented at: International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 3005.
    2. Cascone T, Award MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756-1769. doi:10.1056/NEJM0a2311926
    3. FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer. FDA. October 3, 2024. Accessed September 6, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer
    4. Wahner A. Perioperative nivolumab plus chemotherapy represents the future of personalized NSCLC care. November 14, 2024. Access September 6, 2025. https://www.onclive.com/view/perioperative-nivolumab-plus-chemotherapy-represents-the-future-of-personalized-nsclc-care
    5. Provencio M, Awad MM, Spicer J, et al. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. J Clin Oncol. 2024;42(suppl 17):LBA8007. doi:10.1200/JCO.2024.42.17_suppl.LBA8007

    Continue Reading

    September 7, 2025
  • ‘The Hunting Wives’ Star Malin Akerman Talks Possible Second Season

    ‘The Hunting Wives’ Star Malin Akerman Talks Possible Second Season

    Malin Akerman is just as eager as her newfound fans about a possible season two of The Hunting Wives.

    While speaking to reporters at the Creative Arts Emmys Saturday with her co-star Brittany Snow, Akerman admitted that “we’re asking the same questions” about whether Netflix will bring back their raunchy Texas show.

    “We feel positive from all the feedback that we’ve had from people,” said Akerman, who is presenting with Snow at the Creative Arts Emmys. “But nothing to report yet.”

    “We’re feeling hopeful,” added Snow.

    Deadline recently reported that Lionsgate is in advanced negotiations with Netflix for a Season 2 renewal of the drama. It dropped July 21 as part of a one-year U.S. licensing deal with Lionsgate, after launching on Stan in Australia, Crave in Canada, OSN in the Middle East and HOT in Israel.

    Originally developed for Starz, The Hunting Wives became a massive hit for Netflix. Launched with little fanfare and with no formal promotional campaign on a Monday, the series turned into a staple on Netflix’s U.S. Top 10 for six weeks running, including a stint at No.1 , and also spent its first five weeks in the Global Top 10 despite not being available outside of the U.S.

    “We had no idea it was going to hit like this,” Akerman told reporters. “We originally made it for Starz, and so we thought that it would be for an audience that was geared specifically toward an adult theme. We thought people would see it, but when it got sold to Netflix, we actually freaked out a little bit because we knew that a lot more people would see it. And then to have to many eyes on us doing very adult things.”

    “I really like that people are passionate about, whether they love it or hate it,” she continued. “At least they have an opinion about it. And I welcome that, because it gets people talking, and it’s something to be proud of.”

    To get a Season 2 renewal, the series would have to become a Netflix original, which requires global rights. That is the hurdle Lionsgate has to overcome to secure the pickup, with the studio’s distribution team hard at work to secure those rights from current local buyers.

    Continue Reading

    September 7, 2025
  • Apple Revamps Battery Settings in iOS 26 With Smarter Power Tools

    Apple Revamps Battery Settings in iOS 26 With Smarter Power Tools

    Apple has packed several new battery features into iOS 26, giving iPhone users better tools to track what’s draining power and smarter options to extend battery life.

    The Battery section in Settings has been overhauled with a cleaner look and more context. At the top, users see the current charge level and the last time the device was plugged in. If the iPhone is charging, the screen also shows how long it will take to reach a full charge.

    Instead of only displaying data for the past 24 hours or 10 days, iOS 26 introduces a weekly breakdown of average battery use. A new comparison chart highlights whether you’re consuming more, less, or the same amount of power compared to your typical habits.

    Apps that are responsible for a heavier drain stand out in orange. Apple now specifies whether the issue came from background activity, screen time, or even a surge in notifications. Users can also enable alerts to be notified when battery use spikes above normal.

    Detailed day-by-day tracking is still available for the past week, including active versus idle screen usage and charging sessions. The Battery Health section remains intact, offering cycle counts and maximum capacity, alongside the Charge Limit feature that caps charging at 80 percent.

    Adaptive Power Joins Low Power Mode

    Apple has added a new setting called Adaptive Power Mode, designed to complement Low Power Mode. Instead of aggressively throttling the phone, Adaptive Power makes smaller tweaks, lowering brightness, slowing background tasks, and automatically switching on Low Power Mode when the battery hits 20 percent.

    Adaptive Power mode

    The feature is opt-in and can be found under Battery settings. Once enabled, it activates automatically whenever the iPhone detects unusually high usage. Because it relies on Apple Intelligence, Adaptive Power is only available on the iPhone 15 Pro and newer models.

    Smarter Notifications for Power Management

    Adaptive Power can also notify users when it detects heavy drain and steps in. Those who prefer a quieter experience can leave notifications off, letting the feature work invisibly in the background.

    Charging Time at a Glance

    iphone charging time

    Plugging in an iPhone on iOS 26 now offers more context. With the display off, a quick tap wakes the screen and shows how long until the device is fully charged or until it reaches a user-defined charging limit. The same information is available inside the Battery section of Settings.

    Low Power Mode in Dynamic Island

    When the battery drops to 20 percent, the warning now surfaces in the Dynamic Island. A quick tap on the prompt enables Low Power Mode immediately.

    Clearer Status Icons

    According to the source, Apple has also refined the battery indicator. If charging is paused due to optimized charging settings or high temperature, the battery icon switches to gray instead of the usual green, giving users a more accurate picture of what’s happening.

    Continue Reading

    September 7, 2025
  • Economists on high alert as Trump threatens chips tariffs — Capital Brief

    Economists on high alert as Trump threatens chips tariffs — Capital Brief

    Household spending and consumer sentiment data will be closely watched by economists this week amid signs of a consumer recovery. But it’s international economic turbulence that’s expected to dominate attention.

    Here’s what you need to know about the key economic data releases this week.

    Trump’s chips tariffs

    The news: US trade uncertainty will be back in the spotlight this week on multiple fronts, following the US Appeals Court upholding the decision last week that reciprocal and fentanyl-related tariffs imposed by US President Donald Trump are illegal.

    This will take some time to play out, with a Supreme Court decision potentially not due until early next year and several other avenues potentially available to the Trump administration. But there are still implications for those keeping score.

    Continue Reading

    September 7, 2025
  • Sugary drinks harm gut DNA, Technion rinds reversal

    Sugary drinks harm gut DNA, Technion rinds reversal | The Jerusalem Post

    Jerusalem Post/Health & Wellness/Nutrition

    They explained that bacteria in the gastrointestinal system are vital members of the microbial community within our body, which is known to scientists as the microbiome.

    PROF. NAAMA Geva-Zatorsky.
    PROF. NAAMA Geva-Zatorsky.
    (photo credit: STUDIO LUCIDO)
    ByJUDY SIEGEL-ITZKOVICH
    SEPTEMBER 7, 2025 03:23



    Continue Reading

    September 7, 2025
  • Michelin-starred chef Massimo Bottura reveals his F1 heroes

    Michelin-starred chef Massimo Bottura reveals his F1 heroes

    Massimo Bottura is one of the world’s most highly-regarded chefs, and owner of the three Michelin-starred Osteria Francescana in his native Modena, in Italy – while he’s also the man in charge of Ferrari’s legendary Ristorante Cavallino in Maranello. Speaking exclusively to F1.com, the dynamic culinary colossus gives us an insight into his F1 heroes, his love of the sport – and how to make a ‘Spaghetti Lewis’…

    Who is my F1 hero? Contemporary? From the past? It all depends…

    I think about Charles Leclerc, and I think he’s an amazing driver.

    Then I think about Ayrton Senna, and he so was incredible – even if he wasn’t driving a Ferrari! But if you talk about emotion, Gilles Villeneuve. He was crazy. I admired the intrepid spirit of the chevalier – you know, like a cavalier, a horse rider, but instead of the horse he was riding the Ferrari!

    Continue Reading

    September 7, 2025
←Previous Page
1 … 256 257 258 259 260 … 6,683
Next Page→
  • Blog
  • About
  • FAQs
  • Authors
  • Events
  • Shop
  • Patterns
  • Themes

Twenty Twenty-Five

Designed with WordPress